Atyr Pharma Inc (NASDAQ: ATYR) is -12.98% lower on its value in year-to-date trading and has touched a low of $1.42 and a high of $4.66 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATYR stock was last observed hovering at around $3.03 in the last trading session, with the day’s gains setting it 0.12%.
Currently trading at $3.15, the stock is -16.42% and -14.19% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.83 million and changing 3.96% at the moment leaves the stock 21.33% off its SMA200. ATYR registered 64.92% gain for a year compared to 6-month gain of 68.45%.
The stock witnessed a -11.76% loss in the last 1 month and extending the period to 3 months gives it a -10.76%, and is -18.60% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.46% over the week and 8.96% over the month.
Atyr Pharma Inc (ATYR) has around 59 employees, a market worth around $264.42M and $0.23M in sales. Profit margin for the company is -27155.74%. Distance from 52-week low is 121.83% and -32.40% from its 52-week high. The company has generated returns on investments over the last 12 months (-82.15%).
The EPS is expected to grow by 3.09% this year, but quarterly earnings will post -53.05% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
The shares outstanding are 83.94M, and float is at 81.24M with Short Float at 5.36%.
Atyr Pharma Inc (ATYR) Insider Activity
A total of 0 insider transactions have happened at Atyr Pharma Inc (ATYR) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Broadfoot Jill Marie, the company’s Chief Financial Officer. SEC filings show that Broadfoot Jill Marie sold 1,254 shares of the company’s common stock on Feb 04 ’25 at a price of $3.78 per share for a total of $4740.0. Following the sale, the insider now owns 31763.0 shares.
Atyr Pharma Inc disclosed in a document filed with the SEC on Feb 04 ’25 that DENYES NANCY (General Counsel) sold a total of 899 shares of the company’s common stock. The trade occurred on Feb 04 ’25 and was made at $3.78 per share for $3398.0. Following the transaction, the insider now directly holds 26555.0 shares of the ATYR stock.
Still, SEC filings show that on Jul 24 ’24, SCHIMMEL PAUL (Director) acquired 52,300 shares at an average price of $1.93 for $0.1 million. The insider now directly holds 413,023 shares of Atyr Pharma Inc (ATYR).
